Influence of P53 Expression in Clinical Outcome and Prognostic Factors in Iranian Breast Cancer Patients

Breast cancer (BC) is the most common visceral cancer among Iranian women with 13400 new cases annually. A few studies have reported that BC patients with p53 expression had different prognosis and clinical outcome. The aim of the present study was to evaluate and compare clinical outcome and prognostic factors in Iranian breast cancer patients with p53 expression.

Methods and materials:

 In a longitudinal study, 801 BC patients who had referred to and were followed by Cancer Research Center, from 2003 to 2017, were divided into two groups: 300 patients with p53 expression (positive) and 501 patients without p53 expression (negative). Then, clinical outcome and prognostic factors for these two gr oups were evaluated and compared. 

The patients with positive and negative p53 represented %37.5 and %62.5 of the cases with the mean ages of 44.2 years (SD=9.4) and 47.7 years (SD=10.9), respectively (p<0.0001). There were more advanced stage and lymph node involvement, more positive lymphovascular invasion and Premenopausal status, higher degrees of negative estrogen receptor (ER) status, and positive human epidermal receptor 2 (HER2) expression in patients with positive p53 in comparison to those with negative p53 (p=0.0162, p=0.0047, p=0.0296, p=0.0339, p=0.0374, and p=0.0494, respectively). In patients with positive and negative p53, five years disease free survival were %81 and 86.4 %, (p=0.0413) and five years overall survival wer e %70 and 76.8 %, respectively (p=0.0323). 

Our study showed better clinical outcomes and favorable prognostic factors in patients without p53 expression compared with those with p53 expression.